PALO ALTO, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (BULLETIN BOARD: AVGO) , a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases announced today that Chief Executive Officer Dr. Belinda Tsao-Nivaggioli will present an overview of the company's ongoing product development programs at 1:30 EDT on August 20, 2007, at the Noble Financial Two Double-0-Seven Conference at the Charleston Place Hotel in Charleston, S.C.
The audio and slide presentation will be available on Avicena's website http://www.avicenagroup.com/ and Noble Financial's conference web site at http://www.two-007.net/. A replay will be available at these addresses after the live presentation and will be archived for 90 days.
ABOUT AVICENA
Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
Contact:
The Ruth Group (on behalf of Avicena Group)
Sara Ephraim / (investors)
(646) 536-7029 / 7002
